StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
COLLCOLLEGIUM PHARMACEUTICAL, INC
stockpulse.co.kr
Nasdaq
$22.95▼ 0.09%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $744.4MShares out 32.4M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

9
  • 5d agoAfter-hours26.10.20 05:05
    8-KKey event#●●●#●●●

    COLLEGIUM PHARMACEUTICAL, INCBullish

    Collegium Pharmaceutical has reached a settlement with Grünenthal to resolve all disputes, including the Nucynta patent litigation, for a payment of $17 million. Under the agreement, the existing license agreement was terminated effective October 15, 2026, discharging the company from all future royalty obligations and resulting in the assignment of certain patents to the company.…more

    $22.95-0.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.8After-hours26.10.09 07:27
    SCHEDULE 13G/AOwnership

    COLLEGIUM PHARMACEUTICAL, INC

    Integrated Core Strategies (US) LLC, Millennium Management LLC, and related entities have entered into a joint filing agreement for the Schedule 13G regarding their beneficial ownership of Collegium Pharmaceutical, Inc. common stock. This agreement, dated October 7, 2026, facilitates the joint reporting of equity holdings in accordance with Rule 13d-1(k) of the Securities Exchange Act.…more

    $22.95-0.09%vs prev close
    View filingShare
  • 9.30Regular26.10.01 04:52
    144Ownership

    COLLEGIUM PHARMACEUTICAL, INC

    Scott Dreyer of Collegium Pharmaceutical has filed an SEC Form 144 to report the proposed sale of company shares. This filing formally declares the insider's intention to sell their holdings in the open market.…more

    $22.95-0.09%vs prev close
    View filingShare

8 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 3d agoPre-market26.10.22 21:00
    #●●●#●●●

    Collegium Pharmaceutical to Report Q3 2026 Financial Results on November 5…more

    Collegium Pharmaceutical announced that it will release its financial results for the third quarter of 2026 before the market opens on November 5, 2026. A live conference call and webcast will follow the announcement to discuss the company's performance.…more

    $22.95-0.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 4d agoPre-market26.10.21 21:00

    ●●●●●●●● ●●●●● ●●●●●●

    Collegium Pharmaceutical announced it will present clinical and real-world research findings regarding its ADHD treatments, AZSTARYS and JORNAY PM, at two upcoming medical congresses. These presentations focus on academic data and patient outcomes, representing standard scientific activity rather than immediate financial catalysts.…more

    $22.95-0.09%vs prev close
    Read sourceShareGlobeNewswire
  • 5d agoAfter-hours26.10.20 05:30

    ●●●●●●●● ●●●●● ●●●●●●

    Collegium Pharmaceutical has reached a settlement with Grünenthal to resolve patent litigation for a payment of $17 million. This agreement terminates the license and eliminates future royalty obligations, resolving the legal dispute.…more

    $22.95-0.09%vs prev close
    ShareBenzinga

2 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →